Clinical Trial Update: Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating whether pegylated interferon alfa-2b can reduce relapse after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegylated Interferon Alfa-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: Huashan Hospital | Conditions: Chronic Hepatitis B | Phase 4 | Status: NOT_YET_RECRUITING